← Back to Search

Text Messaging for Leukemia

N/A
Waitlist Available
Led By Wendy Stock
Research Sponsored by University of Chicago
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Diagnosed with ALL
Age of 15-39 years-old at the time of initial ALL diagnosis
Must not have
Patient does not wish to participate
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 year
Awards & highlights
No Placebo-Only Group

Summary

This trial aims to see if text message reminders can help adolescents and young adults with acute lymphoblastic leukemia to remember to take their chemotherapy medications regularly.

Who is the study for?
This trial is for young people aged 15-39 who were diagnosed with Acute Lymphoblastic Leukemia (ALL) and are starting maintenance treatment that includes mercaptopurine and methotrexate. They must want to participate and have a cell phone capable of receiving text messages.
What is being tested?
The study tests if text message reminders can help adolescents and young adults take their oral chemotherapy medications more consistently. Participants will receive either high intensity, low intensity, or no text messaging as part of the intervention.
What are the potential side effects?
Since this trial focuses on the use of text messaging as an intervention, there are no direct medical side effects associated with it. However, participants continue their usual chemotherapy regimen which may have its own side effects.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have been diagnosed with Acute Lymphoblastic Leukemia (ALL).
Select...
I was diagnosed with ALL between the ages of 15 and 39.
Select...
I am starting maintenance treatment with mercaptopurine and methotrexate.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I do not want to join the clinical trial.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 year
This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 year for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
To compare adherence to oral chemotherapy with mercaptopurine and methotrexate
Secondary study objectives
To describe the relationship between oral chemotherapy adherence and AYA patient factors
Other study objectives
To compare clinical outcomes during and after maintenance therapy for AYA patients
To compare percentage of time during maintenance at goal absolute neutrophil count (ANC) and platelet count for AYA patients

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Active Control
Group I: High IntensityActive Control1 Intervention
Receives high-intensity text messaging for 2 cycles of treatment
Group II: Low IntensityActive Control2 Interventions
Receives no texts for 1st cycle and low-intensity texts for 2nd cycle

Find a Location

Who is running the clinical trial?

University of ChicagoLead Sponsor
1,053 Previous Clinical Trials
759,036 Total Patients Enrolled
Wendy StockPrincipal InvestigatorUniversity of Chicago
3 Previous Clinical Trials
389 Total Patients Enrolled
~25 spots leftby Jun 2027
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top